The present study reports the synthesis of a novel compound with the formula [Ru
2(aGLA)4Cl] according to elemental analyses data, referred to as Ru
2GLA. The electronic spectra of Ru
2GLA is typical of a mixed valent diruthenium(II,III) carboxylate. Ru
2GLA was synthesized with the aim of combining and possibly improving the anti‐tumour properties of the two active components ruthenium and
γ‐linolenic acid (GLA). The properties of Ru
2GLA were tested in C6 rat glioma cells by analysing cell number, viability, lipid droplet formation, apoptosis, cell cycle distribution, mitochondrial membrane potential and reactive oxygen species. Ru
2GLA inhibited cell proliferation in a time and concentration dependent manner. Nile Red staining suggested that Ru
2GLA enters the cells and ICP‐AES elemental analysis found an increase in ruthenium from <0.02 to 425 mg/Kg in treated cells. The sub‐G1 apoptotic cell population was increased by Ru
2GLA (22 ± 5.2%) when analysed by FACS and this was confirmed by Hoechst staining of nuclei. Mitochondrial membrane potential was decreased in the presence of Ru
2GLA (44 ± 2.3%). In contrast, the cells which maintained a high mitochondrial membrane potential had an increase (18 ± 1.5%) in reactive oxygen species generation. Both decreased mitochondrial membrane potential and increased reactive oxygen species generation may be involved in triggering apoptosis in Ru
2GLA exposed cells. The EC
50 for Ru
2GLA decreased with increasing time of exposure from 285 µM at 24 h, 211 µM at 48 h to 81 µM at 72 h. In conclusion, Ru
2GLA is a novel drug with antiproliferative properties in C6 glioma cells and is a potential candidate for novel therapies in gliomas. Copyright © 2009 John Wiley & Sons, Ltd.
相似文献